UGT1A1 Genotype-guided Phase I Study of Irinotecan, Oxaliplatin, and Capecitabine

PURPOSE: We performed a UGT1A1 genotype-guided study to determine the maximum tolerated dose (MTD) and evaluate the toxicities and pharmacokinetics of the combination of capecitabine (CAP), oxaliplatin (OX), and irinotecan (IRIN). EXPERIMENTAL DESIGN: Patients were screened for UGT1A1 *28 genotype p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Goetz, Matthew P., McKean, Heidi A., Reid, Joel M, Mandrekar, Sumithra J., Tan, Angelina D., Kuffel, Mary A., Safgren, Stephanie L., McGovern, Renee M., Goldberg, Richard M., Grothey, Axel A., McWilliams, Robert, Erlichman, Charles, Ames, Matthew M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3880122/
https://ncbi.nlm.nih.gov/pubmed/24114122
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-0034-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados